Display options
Cite
, Appleton CA, Caldwell G, et al. Recommendations for lipid testing and reporting by Australian pathology laboratories. Clin Biochem Rev. 2007;28(2):32-45
, Appleton, C. A., Caldwell, G., McNeil, A., Meerkin, M., Sikaris, K., Sullivan, D. R., Thomas, D. W., & Tognarini, D. P. (2007). Recommendations for lipid testing and reporting by Australian pathology laboratories. The Clinical biochemist. Reviews, 28(2), 32-45.
, et al. "Recommendations for lipid testing and reporting by Australian pathology laboratories." The Clinical biochemist. Reviews vol. 28,2 (2007): 32-45.
, Appleton CA, Caldwell G, McNeil A, Meerkin M, Sikaris K, Sullivan DR, Thomas DW, Tognarini DP. Recommendations for lipid testing and reporting by Australian pathology laboratories. Clin Biochem Rev. 2007 May;28(2):32-45. PMID: 17687413; PMCID: PMC1904423.
Copy Download .nbib Format: NLM
Share it on

Clin Biochem Rev. 2007 May;28(2):32-45.

Recommendations for lipid testing and reporting by Australian pathology laboratories.

The Clinical biochemist. Reviews

Charles A Appleton, Grahame Caldwell, Alan McNeil, Matthew Meerkin, Ken Sikaris, David R Sullivan, David W Thomas, David P Tognarini

PMID: 17687413 PMCID: PMC1904423

Abstract

The importance of measuring blood lipids in determining the absolute risk of a cardiovascular event is now well established. In Australia, the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (NHFA/CSANZ) have done much to educate doctors. In recent years the recommendations of the NHFA/CSANZ have been based on values for Low-density lipoprotein (LDL-C) as well as High-density lipoprotein cholesterol (HDL-C) and Triglyceride (TG). This change has been reflected in requests to pathology laboratories. However the interpretation of these results may be difficult and the NHFA guidelines outline desirable values for patients at high risk only. There are no formal recommendations for reference intervals or interpretive comments. With the availability of expert systems, some pathology laboratories are now in a better position to provide specific comments to assist with the interpretation of test results. An ad hoc committee of private and public chemical pathologists met to draft recommendations for lipid testing and reporting by Australian pathology providers, on the basis of current guidelines and their own expertise. Provisions in the current Medicare Benefits Schedule (MBS) for lipid testing were reviewed, and the indications for lipid testing, recommended tests, the logistics of managing specimens, methods of analysis and availability of specialised tests have been documented. Recommendations are made on the provision of desirable values for lipid tests. Suggestions are provided on interpretive comments which could accompany reports of lipid test results, including categorisation of the likely associated lipoprotein abnormalities, their causes, contribution to risk for cardiovascular disease (CVD) and targets for treatment. Current and future approaches to the assessment of risk for CVD are discussed.

References

  1. Atherosclerosis. 2003 May;168(1):1-14 - PubMed
  2. Am J Cardiol. 2006 Apr 17;97(8A):89C-94C - PubMed
  3. Am J Cardiol. 2003 May 15;91(10):1173-7 - PubMed
  4. Heart Lung Circ. 2005 Dec;14(4):275-91 - PubMed
  5. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
  6. Clin Chem. 1993 Jun;39(6):1012-22 - PubMed
  7. World J Gastroenterol. 2006 Nov 28;12(44):7197-202 - PubMed
  8. Circulation. 1980 Nov;62(4 Pt 2):IV116-36 - PubMed
  9. Med J Aust. 2001 Nov 5;175(S2):S62-85 - PubMed
  10. N Engl J Med. 2006 Dec 21;355(25):2631-9 - PubMed

Publication Types